Sexual & SkinResearch profile

PT-141

Bremelanotide · Vyleesi · PT141 · Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Think of it as a jumpstart for your brain's desire engine.

PT-141 is like a little nudge for your brain when it comes to getting in the mood. Unlike other options that work more like a physical switch in the body, this one taps into your central system, sparking desire from the top down. It's been shown to help reignite interest and reduce stress about lack of desire in premenopausal women.

For men, some early research hinted it could help with arousal, even if other common methods didn't work, but that's not its main gig right now. Instead, PT-141 is all about activating specific brain pathways linked to sexual excitement and desire, making it a unique player in the field.

Who it's for

Women looking to boost sexual desire naturally.
Individuals curious about alternatives to traditional arousal enhancers.
Those interested in brain-centric approaches to intimacy.

Probably not for you if…

Men seeking treatment for erectile dysfunction specifically.
Anyone uncomfortable with injections or who dislikes needles.
Individuals looking for over-the-counter solutions.

Editorial summary for research context · Not medical advice

Mechanism of Action

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-MSH that acts as a non-selective agonist at melanocortin receptors, with functional activity primarily at MC3R and MC4R in the central nervous system. Unlike vasodilator-based therapies, PT-141 works upstream through central hypothalamic pathways implicated in sexual desire and arousal. It is FDA-approved as Vyleesi (AMAG Pharmaceuticals, 2019) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, administered subcutaneously at a fixed dose at least 45 minutes before anticipated activity. Prescription required.

Researched Benefits

Central sexual desire modulation (HSDD)

Phase 3 RECONNECT trials demonstrated statistically significant improvements in desire and reductions in distress versus placebo in premenopausal women with HSDD, supporting FDA approval of Vyleesi.

[Kingsberg et al. 2019 (Obstet Gynecol)]
[Simon et al. 2019]

Arousal response in erectile dysfunction research

Earlier Phase 2 studies in men with ED (including PDE5-non-responders) showed improvements in erectile response under research conditions, though the indication was not pursued commercially after BP signal concerns.

[Diamond et al. 2004]
[Rosen et al. 2004]

Melanocortin pathway signaling

Pharmacology research confirms MC4R-mediated activation of hypothalamic nuclei (PVN, MPOA) involved in pro-sexual signaling, distinct from peripheral vascular mechanisms.

[Pfaus et al. 2007]

Research Protocols

The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.

FDA-approved (Vyleesi) regimen — HSDD

Dosage: 1.75 mg
Frequency: as-needed, max 1 dose per 24h
Timing: ≥45 minutes before anticipated activity
Cycle: 8 weeks

Per FDA labeling: single 1.75 mg subcutaneous auto-injector dose, no more than once in 24 hours and not more than 8 doses per month. Prescription required. Discontinue if no benefit after 8 weeks.

Research-literature dose range

Dosage: 1 mg
Frequency: as-needed
Timing: 45-60 minutes pre-activity
Cycle: 4 weeks

Published trials have explored 0.75-2.0 mg SC. Higher doses associated with increased nausea and transient BP elevation. For research documentation only.

Reported Side Effects

Nausea (most common; ~40% in trials, typically first dose)
Flushing and headache
Injection-site reactions
Transient increases in systolic/diastolic blood pressure (monitor in at-risk patients)
Focal hyperpigmentation with repeated dosing (MSH pathway)
Rare: vomiting, fatigue

Contraindications

Uncontrolled hypertension or established cardiovascular disease (BP elevation risk)
Pregnancy and lactation
Personal or family history of melanoma or active skin cancer
Postmenopausal women (not studied / not indicated)
Concurrent use of oral naltrexone (reduces naltrexone exposure)

Stacking Partners

Peptides commonly paired with PT-141 in published research and protocol write-ups.

sexual skin

Vendor Pricing

74
NextGen Peptides
Best $/mg
Size10mg
Total$24.99
/ mg$2.50/mg
In stock
View
67
Ignite Peptides
Size10mg
Total$30.00
/ mg$3.00/mg
In stock
View
67
Puratek Peptides
Size10mg
Total$31.45
/ mg$3.15/mg
In stock
View
66
Guru Peptides
Size10mg
Total$31.99
/ mg$3.20/mg
In stock
View
74
Modern Research Peptides
Size10mg
Total$32.99
/ mg$3.30/mg
In stock
View
67
True Peptide Labs
Size10mg
Total$36.00
/ mg$3.60/mg
In stock
View
73
Royal Peptides
Size100mg
Total$390.00
/ mg$3.90/mg
In stock
View
67
Helixion Labs
Size10mg
Total$39.99
/ mg$4.00/mg
In stock
View

Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.

Gear + Companions

Reconstitution supplies and research-backed supplement companions for PT-141. Editorial picks only — we earn a commission through Amazon on the click, no sponsorship.

Gear you'll need

· Reconstitution + storage essentials

Bacteriostatic Water 30mL (0.9% Benzyl Alcohol)
Empower Pharmacy / generic medical supply
Reconstitutes every lyophilized peptide. 28-day viability refrigerated.
View at Pantheon →
Insulin Syringes 31G × 5/16" × 0.5mL (100 count)
EasyTouch
31G × 0.5mL insulin syringes — the default size for sub-0.25mL peptide doses.
Buy on Amazon →
Alcohol Prep Pads (Sterile, 200 count)
Dynarex
Sterile 70% IPA prep pads — one per vial stopper + one per injection site.
Buy on Amazon →
1-Quart Sharps Disposal Container
BD / Becton Dickinson
FDA-cleared sharps container — pharmacies won't accept improvised disposal.
Buy on Amazon →

Stacks well with

· Supplement companions — independent evidence, not sponsored

L-Citrulline Malate 1kg Unflavored Powder
BulkSupplements
Central + peripheral NO signaling stack — PT-141 works on the brain, L-citrulline on the vasculature.
Buy on Amazon →

As an Amazon Associate we earn from qualifying purchases · Disclosed per FTC guidelines

Research Papers

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D, et al. · Obstetrics & Gynecology · 2019
PubMed 31403595 →
Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder
Simon JA, Kingsberg SA, Portman D, et al. · Obstetrics & Gynecology · 2019
PubMed 31403594 →
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties, and pharmacodynamic effects of intranasal PT-141 in healthy male subjects
Diamond LE, Earle DC, Rosen RC, et al. · International Journal of Impotence Research · 2004
PubMed 14963469 →

PT-141

Mechanism of Action